Publications

Persi E, Prandi D, Wolf YI, Pozniak Y, Barnabas GD, Levanon K, Barshack I, Barbieri C, Gasperini P, Beltran H et al..  2019.  Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues.. Proc Natl Acad Sci U S A. 116(34):16987-16996.

Shohdy KS, Vlachostergios PJ, Abdel-Malek RR, Faltas BM.  2019.  Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma.. Expert Opin Ther Targets. 23(2):83-86.

Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyrta J et al..  2019.  Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.. Nat Commun. 10(1):2977.

Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P et al..  2018.  Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.. Cancer.

Faltas BM, Gennarelli RL, Elkin E, Nguyen DP, Hu J, Tagawa ST.  2018.  Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes. Urol Oncol. 36(1):9.e11-9.e17.

Vlachostergios PJ, Faltas BM.  2018.  Treatment resistance in urothelial carcinoma: an evolutionary perspective.. Nat Rev Clin Oncol.

Faltas BM, Tagawa ST.  2017.  Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancer. Lancet. 389(10064):6-7.

Pisapia D, Salvatore S., Pauli C., Hissong E., Prandi D., Sailer V.-W., Robinson B, Park K., Cyrta J., Tagawa S.T. et al..  2017.  Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO Precision Oncology. (1):1-13.

Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov. 7(5):462-477.

Mikhail S, Faltas B, Salem ME, Bekaii-Saab T.  2016.  Application of next-generation sequencing in gastrointestinal and liver tumors. Cancer Lett. 374(2):187-91.

Alme AKB, Karir BS, Faltas BM, Drake CG.  2016.  Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol. 34(4):171-81.

Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JMiguel, Robinson B, Elemento O et al..  2016.  Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet. 48(12):1490-1499.

Dutta R, Abdelhalim A, Martin JW, Vernez SL, Faltas B, Lotan Y, Youssef RF.  2016.  Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. Urol Oncol. 34(12):531.e1-531.e6.

Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, Hajdenberg J, Hodes G, Nanus DM, Tagawa ST.  2016.  Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Clin Genitourin Cancer. 14(1):e75-9.

Faltas BM, Karir BS, Tagawa ST, Rosenberg JE.  2015.  Novel molecular targets for urothelial carcinoma. Expert Opin Ther Targets. 19(4):515-25.

Nguyen DP, Awamlh BAl Hussein, Faltas BM, O'Malley P, Ayangbesan A, Inoyatov IM, Scherr DS.  2015.  Radical Cystectomy for Bladder Cancer in Patients With and Without a History of Pelvic Irradiation: Survival Outcomes and Diversion-related Complications. Urology. 86(1):99-106.

Nguyen DP, Awamlh BAl Hussein, Wu X, O'Malley P, Inoyatov IM, Ayangbesan A, Faltas BM, Christos PJ, Scherr DS.  2015.  Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer. Eur Urol. 68(3):399-405.

Beltran H, Eng K, Mosquera JMiguel, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J et al..  2015.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol. 1(4):466-74.

Diamond E, Riches J, Faltas B, Tagawa ST, Nanus DM.  2014.  Immunologics and chemotherapeutics for renal cell carcinoma. Semin Intervent Radiol. 31(1):91-7.

Andrei M, Cramer SF, Kramer ZB, Zeidan A, Faltas B.  2013.  Adult primary pulmonary primitive neuroectodermal tumor: molecular features and translational opportunities. Cancer Biol Ther. 14(2):75-80.

Faltas B, Zeidan A, Gergis U.  2013.  Myelodysplastic syndromes: toward a risk-adapted treatment approach. Expert Rev Hematol. 6(5):611-24.

Zeidan AM, Faltas B, B Smith D, Gore S.  2013.  Myelodysplastic syndromes: what do hospitalists need to know? J Hosp Med. 8(6):351-7.

Zeidan A, Faltas B, Forde P, Subhawong A, Bello C, Bolaños-Meade J.  2013.  Sequential occurrence of a splenic marginal zone lymphoma, extranodal MALT lymphoma, and Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 13(4):496-8.

Zeidan A, Faltas B, Fricke W, Gore S, Ketterling R, Sham R.  2013.  Sustained remission in a patient with myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma. Leuk Lymphoma. 54(7):1534-7.

Faltas B.  2012.  Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells. Front Oncol. 2:68.